Health Care & Life Sciences » Pharmaceuticals | Walvax Biotechnology Co. Ltd.

Walvax Biotechnology Co. Ltd. | Income Statement

Fiscal year is January-December. All values CNY Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
578,596.30
705,177.40
998,538.90
583,545.60
656,654.00
869,043.60
Cost of Goods Sold (COGS) incl. D&A
250,239.20
487,020.50
614,657.80
329,854.70
249,109.20
227,022.10
Gross Income
328,357.20
218,156.90
383,881.10
253,690.80
407,544.80
642,021.50
SG&A Expense
274,083.90
470,717.60
581,253.60
318,960.80
495,902.80
578,319
EBIT
49,765.20
266,877.90
234,692.20
19,698.90
93,010.70
53,396.80
Unusual Expense
-
552,535.30
523,889.60
-
2,034.60
1,867.70
Non Operating Income/Expense
1,026.50
2,265.90
5,770.80
136,499.20
386,154.00
1,121,705.90
Interest Expense
70,568.90
172,795.70
154,038.80
137,342.00
116,065.80
39,980
Pretax Income
10,301.20
143,434.00
888,813.60
15,907.10
583,918.00
1,174,330.30
Income Tax
5,419.40
41,252.20
39,972.40
4,663.60
18,416.70
120,808.10
Equity in Affiliates
-
5,476.70
4,133.30
18,776.90
7,258.50
9,168.90
Consolidated Net Income
4,881.80
96,705.10
924,652.80
30,020.40
558,242.80
1,062,691.10
Net Income
47,893.10
143,424.70
840,895.30
70,458.70
537,137.50
1,046,204.50
Net Income After Extraordinaries
47,893.10
143,424.70
840,895.30
70,458.70
537,137.50
1,046,204.50
Net Income Available to Common
47,893.10
143,424.70
840,895.30
70,458.70
537,137.50
1,046,204.50
EPS (Basic)
0.03
0.10
0.60
0.05
0.35
0.68
Basic Shares Outstanding
1,425,763.40
1,404,001.40
1,404,000.00
1,409,174.00
1,537,437.00
1,537,437
EPS (Diluted)
0.03
0.10
0.60
0.05
0.35
0.68
Diluted Shares Outstanding
1,425,763.40
1,404,001.40
1,404,000.00
1,409,174.00
1,537,437.00
1,537,437
EBITDA
178,082.00
142,924.10
147,565.30
101,454.80
33,158.00
180,455.70
Other Operating Expense
4,508.00
14,317.10
37,319.60
45,571.10
4,652.80
10,305.70
Non-Operating Interest Income
24,192.10
18,641.10
6,653.10
17,743.30
13,347.20
29,981.80
Minority Interest Expense
43,011.30
46,719.50
83,757.50
40,438.30
21,105.30
16,486.70

About Walvax Biotechnology Co.

View Profile
Address
19/F, Building 9A, Dingyi Tiancheng
Kunming Yunnan 650106
China
Employees -
Website http://www.walvax.com
Updated 07/08/2019
Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. Its products include haemophilus influenzae type b conjugate vaccine in vials and pre-encapsulation type; lyophilized type A and C, and ACYW135 meningococcal polysaccharide conjugate vaccine. The company was founded on January 16, 2001 and is headquartered in Kunming, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.